EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models

Manali S Phadke, Jiannong Li, Sathya Sriramareddy, Paulo C Rodriguez, Brian Ruffell, Vincent C Luca, Thuy T T Tran, Yian Ann Chen, Keiran S M Smalley

Journal for ImmunoTherapy of Cancer · 2025-08 · 13 (8) · e012011

DOI: 10.1136/jitc-2025-012011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.08.2025. Verfasst von Manali S Phadke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Microenvironment and Metastasis, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Hepatitis A Virus Cellular Receptor 2, Immunotherapy, Melanoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Florida Department of Health, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A significant percentage of melanomas are refractory to immune checkpoint inhibitor (ICI) monotherapies and combinations. As there are currently no effective second-line therapies available for ICI-resistant patients, we sought to identify novel checkpoint inhibitor combinations for future clinical evaluation.

Methods

We used responding and resistant SM1, SW1 and B16-10 melanoma models to explore the mechanism of action of anti-programmed cell death protein 1 (PD-1)+lymphocyte activation gene (LAG-3), anti-PD-1+cytotoxic lymphocyte associated protein 4 (CTLA-4), the anti-PD-1+LAG-3+CTLA-4 triplet, the anti-PD-1+T-cell immunoglobin and mucin domain 3 (TIM-3) doublet and the anti-PD-1+LAG-3+TIM-3 triplet. Flow cytometry, tetramer binding assays, T-cell depletion and analysis of the tumor-draining lymph nodes were used to determine the mechanisms of action of the ICI combinations. Single-cell RNA sequencing (scRNA-Seq) data from patients with melanoma was additionally analyzed to determine immune checkpoint expression across T-cell subsets and their association with ICI resistance.

Results

The PD-1+CTLA-4+LAG-3 triplet combination had good efficacy in the SM1 and B16-F10 melanoma models and led to a more favorable immune microenvironment (increased CD69+CD8+ T cells and gp-100-tumor specific T cells, reduced exhausted T cells) than either doublet. The ICI-resistant SW1 model did not respond to the PD-1+CTLA-4+LAG-3 triplet and was characterized by an accumulation of TIM-3+terminally exhausted CD8+T cells. Targeting of TIM-3 using the anti-PD-1+LAG-3+TIM-3 triplet led to complete tumor regressions in the SW1 and SM1 models. The TIM-3-based triplet decreased exhausted CD8+T cells and regulatory T cells, increased numbers of gp-100 reactive CD8+T cells and increased progenitor-exhausted CD8+T cells (TCF7+Ki67+ TIM-3−) numbers in tumor-draining lymph nodes. scRNA-Seq analysis demonstrated that TIM-3 levels were higher in the CD8+T cells of patients with melanoma who were non-responsive to immunotherapy. PD-1 and TIM-3 expression was strongly correlated in the CD8+T cells from patients with melanoma, providing the rationale for co-targeting these checkpoints.

Conclusion

Melanoma models characterized by high levels of terminally exhausted CD8+T cells (TIM-3+) can be successfully treated with the anti-PD-1+LAG-3+TIM-3 combination. The observation that high TIM-3 expression in CD8+T cells is associated with ICI resistance suggests the potential utility of anti-TIM-3-based combinations as a second-line treatment strategy in patients with advanced melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsHepatitis A Virus Cellular Receptor 2ImmunotherapyMelanomaMelanoma, ExperimentalAnimalsMiceHumansLymphocyte Activation Gene 3 ProteinDrug Resistance, NeoplasmFemale

Stichwörter der Autor:innen

Immune Checkpoint InhibitorMelanomaT cell

Substanzen

Immune Checkpoint InhibitorsHepatitis A Virus Cellular Receptor 2Lymphocyte Activation Gene 3 ProteinHAVCR2 protein, humanHavcr2 protein, mouse

Autor:innen und Institutionen

  • Department of Tumor Microenvironment and Metastasis, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Departments of Internal Medicine and Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
  • Department of Biostatistics and Bioinformatics, University of Utah, Salt Lake City, Utah, USA.
  • Department of Tumor Microenvironment and Metastasis, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA keiran.smalley@moffitt.org.

Förderung

  • NCI NIH HHS
  • Florida Department of Health
  • NIH

Zitieren

APA

Phadke, M. S., Li, J., Sriramareddy, S., Rodriguez, P. C., Ruffell, B., Luca, V. C., Tran, T. T. T., Chen, Y. A., & Smalley, K. S. M. (2025). Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models. Journal for ImmunoTherapy of Cancer, 13(8), e012011. https://doi.org/10.1136/jitc-2025-012011

Vancouver

Phadke MS, Li J, Sriramareddy S, Rodriguez PC, Ruffell B, Luca VC, et al. Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models. Journal for ImmunoTherapy of Cancer. 2025;13(8):e012011. doi:10.1136/jitc-2025-012011

BibTeX
@article{Phadke2025,
  author = {Phadke, Manali S and Li, Jiannong and Sriramareddy, Sathya and Rodriguez, Paulo C and Ruffell, Brian and Luca, Vincent C and Tran, Thuy T T and Chen, Yian Ann and Smalley, Keiran S M},
  title = {Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {8},
  pages = {e012011},
  doi = {10.1136/jitc-2025-012011}
}
Kostenlos starten →